Global Opioid-Induced Constipation Market Growth 2020-2025
According to this study, over the next five years the Opioid-Induced Constipation market will register a 4.8%% CAGR in terms of revenue, the global market size will reach $ 2895.4 million by 2025, from $ 2402.9 million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Opioid-Induced Constipation business, shared in Chapter 3.
This report presents a comprehensive overview, market shares, and growth opportunities of Opioid-Induced Constipation market by product type, application, key manufacturers and key regions and countries.
This study specially analyses the impact of Covid-19 outbreak on the Opioid-Induced Constipation, covering the supply chain analysis, impact assessment to the Opioid-Induced Constipation market size growth rate in several scenarios, and the measures to be undertaken by Opioid-Induced Constipation companies in response to the COVID-19 epidemic.
Segmentation by type: breakdown data from 2015 to 2020, in Section 2.3; and forecast to 2025 in section 11.7.
Methylnaltrexone Bromide
Lubiprostone
Naloxegol
Others
Segmentation by application: breakdown data from 2015 to 2020, in Section 2.4; and forecast to 2024 in section 11.8.
Hospital
Pharmacy
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
Takeda Pharmaceuticals
Daiichi Sankyo
Bayer
Mallinckrodt
Salix (Bausch Health)
Sanofi
Purdue Pharm
AstraZeneca
Nektar Therapeutics
Progenics Pharmaceuticals
Prestige
Shionogi
GSK
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.
Research objectives
To study and analyze the global Opioid-Induced Constipation consumption (value & volume) by key regions/countries, type and application, history data from 2015 to 2019, and forecast to 2025.
To understand the structure of Opioid-Induced Constipation market by identifying its various subsegments.
Focuses on the key global Opioid-Induced Constipation manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Opioid-Induced Constipation with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Opioid-Induced Constipation submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
1 Scope of the Report
1.1 Market Introduction
1.2 Research Objectives
1.3 Years Considered
1.4 Market Research Methodology
1.5 Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Opioid-Induced Constipation Consumption 2015-2025
2.1.2 Opioid-Induced Constipation Consumption CAGR by Region
2.2 Opioid-Induced Constipation Segment by Type
2.2.1 Methylnaltrexone Bromide
2.2.2 Lubiprostone
2.2.3 Naloxegol
2.2.4 Others
2.3 Opioid-Induced Constipation Consumption by Type
2.3.1 Global Opioid-Induced Constipation Consumption Market Share by Type (2015-2020)
2.3.2 Global Opioid-Induced Constipation Revenue and Market Share by Type (2015-2020)
2.3.3 Global Opioid-Induced Constipation Sale Price by Type (2015-2020)
2.4 Opioid-Induced Constipation Segment by Application
2.4.1 Hospital
2.4.2 Pharmacy
2.5 Opioid-Induced Constipation Consumption by Application
2.5.1 Global Opioid-Induced Constipation Consumption Market Share by Type (2015-2020)
2.5.2 Global Opioid-Induced Constipation Value and Market Share by Type (2015-2020)
2.5.3 Global Opioid-Induced Constipation Sale Price by Type (2015-2020)
3 Global Opioid-Induced Constipation by Company
3.1 Global Opioid-Induced Constipation Sales Market Share by Company
3.1.1 Global Opioid-Induced Constipation Sales by Company (2018-2020)
3.1.2 Global Opioid-Induced Constipation Sales Market Share by Company (2018-2020)
3.2 Global Opioid-Induced Constipation Revenue Market Share by Company
3.2.1 Global Opioid-Induced Constipation Revenue by Company (2018-2020)
3.2.2 Global Opioid-Induced Constipation Revenue Market Share by Company (2018-2020)
3.3 Global Opioid-Induced Constipation Sale Price by Company
3.4 Global Opioid-Induced Constipation Manufacturing Base Distribution, Sales Area, Type by Company
3.4.1 Global Opioid-Induced Constipation Manufacturing Base Distribution and Sales Area by Company
3.4.2 Players Opioid-Induced Constipation Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2018-2020)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 Opioid-Induced Constipation by Regions
4.1 Opioid-Induced Constipation by Regions
4.2 Americas Opioid-Induced Constipation Consumption Growth
4.3 APAC Opioid-Induced Constipation Consumption Growth
4.4 Europe Opioid-Induced Constipation Consumption Growth
4.5 Middle East & Africa Opioid-Induced Constipation Consumption Growth
5 Americas
5.1 Americas Opioid-Induced Constipation Consumption by Countries
5.1.1 Americas Opioid-Induced Constipation Consumption by Countries (2015-2020)
5.1.2 Americas Opioid-Induced Constipation Value by Countries (2015-2020)
5.2 Americas Opioid-Induced Constipation Consumption by Type
5.3 Americas Opioid-Induced Constipation Consumption by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
5.8 Key Economic Indicators of Few Americas Countries
6 APAC
6.1 APAC Opioid-Induced Constipation Consumption by Regions
6.1.1 APAC Opioid-Induced Constipation Consumption by Regions (2015-2020)
6.1.2 APAC Opioid-Induced Constipation Value by Regions (2015-2020)
6.2 APAC Opioid-Induced Constipation Consumption by Type
6.3 APAC Opioid-Induced Constipation Consumption by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 Key Economic Indicators of Few APAC Regions
7 Europe
7.1 Europe Opioid-Induced Constipation by Countries
7.1.1 Europe Opioid-Induced Constipation Consumption by Countries (2015-2020)
7.1.2 Europe Opioid-Induced Constipation Value by Countries (2015-2020)
7.2 Europe Opioid-Induced Constipation Consumption by Type
7.3 Europe Opioid-Induced Constipation Consumption by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
7.9 Key Economic Indicators of Few Europe Countries
8 Middle East & Africa
8.1 Middle East & Africa Opioid-Induced Constipation by Countries
8.1.1 Middle East & Africa Opioid-Induced Constipation Consumption by Countries (2015-2020)
8.1.2 Middle East & Africa Opioid-Induced Constipation Value by Countries (2015-2020)
8.2 Middle East & Africa Opioid-Induced Constipation Consumption by Type
8.3 Middle East & Africa Opioid-Induced Constipation Consumption by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers and Impact
9.1.1 Growing Demand from Key Regions
9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends
10 Marketing, Distributors and Customer
10.1 Sales Channel
10.1.1 Direct Channels
10.1.2 Indirect Channels
10.2 Opioid-Induced Constipation Distributors
10.3 Opioid-Induced Constipation Customer
11 Global Opioid-Induced Constipation Market Forecast
11.1 Global Opioid-Induced Constipation Consumption Forecast (2021-2025)
11.2 Global Opioid-Induced Constipation Forecast by Regions
11.2.1 Global Opioid-Induced Constipation Forecast by Regions (2021-2025)
11.2.2 Global Opioid-Induced Constipation Value Forecast by Regions (2021-2025)
11.2.3 Americas Consumption Forecast
11.2.4 APAC Consumption Forecast
11.2.5 Europe Consumption Forecast
11.2.6 Middle East & Africa Consumption Forecast
11.3 Americas Forecast by Countries
11.3.1 United States Market Forecast
11.3.2 Canada Market Forecast
11.3.3 Mexico Market Forecast
11.3.4 Brazil Market Forecast
11.4 APAC Forecast by Countries
11.4.1 China Market Forecast
11.4.2 Japan Market Forecast
11.4.3 Korea Market Forecast
11.4.4 Southeast Asia Market Forecast
11.4.5 India Market Forecast
11.4.6 Australia Market Forecast
11.5 Europe Forecast by Countries
11.5.1 Germany Market Forecast
11.5.2 France Market Forecast
11.5.3 UK Market Forecast
11.5.4 Italy Market Forecast
11.5.5 Russia Market Forecast
11.6 Middle East & Africa Forecast by Countries
11.6.1 Egypt Market Forecast
11.6.2 South Africa Market Forecast
11.6.3 Israel Market Forecast
11.6.4 Turkey Market Forecast
11.6.5 GCC Countries Market Forecast
11.7 Global Opioid-Induced Constipation Forecast by Type
11.8 Global Opioid-Induced Constipation Forecast by Application
12 Key Players Analysis
12.1 Takeda Pharmaceuticals
12.1.1 Company Information
12.1.2 Opioid-Induced Constipation Product Offered
12.1.3 Takeda Pharmaceuticals Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2018-2020)
12.1.4 Main Business Overview
12.1.5 Takeda Pharmaceuticals Latest Developments
12.2 Daiichi Sankyo
12.2.1 Company Information
12.2.2 Opioid-Induced Constipation Product Offered
12.2.3 Daiichi Sankyo Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2018-2020)
12.2.4 Main Business Overview
12.2.5 Daiichi Sankyo Latest Developments
12.3 Bayer
12.3.1 Company Information
12.3.2 Opioid-Induced Constipation Product Offered
12.3.3 Bayer Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2018-2020)
12.3.4 Main Business Overview
12.3.5 Bayer Latest Developments
12.4 Mallinckrodt
12.4.1 Company Information
12.4.2 Opioid-Induced Constipation Product Offered
12.4.3 Mallinckrodt Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2018-2020)
12.4.4 Main Business Overview
12.4.5 Mallinckrodt Latest Developments
12.5 Salix (Bausch Health)
12.5.1 Company Information
12.5.2 Opioid-Induced Constipation Product Offered
12.5.3 Salix (Bausch Health) Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2018-2020)
12.5.4 Main Business Overview
12.5.5 Salix (Bausch Health) Latest Developments
12.6 Sanofi
12.6.1 Company Information
12.6.2 Opioid-Induced Constipation Product Offered
12.6.3 Sanofi Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2018-2020)
12.6.4 Main Business Overview
12.6.5 Sanofi Latest Developments
12.7 Purdue Pharm
12.7.1 Company Information
12.7.2 Opioid-Induced Constipation Product Offered
12.7.3 Purdue Pharm Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2018-2020)
12.7.4 Main Business Overview
12.7.5 Purdue Pharm Latest Developments
12.8 AstraZeneca
12.8.1 Company Information
12.8.2 Opioid-Induced Constipation Product Offered
12.8.3 AstraZeneca Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2018-2020)
12.8.4 Main Business Overview
12.8.5 AstraZeneca Latest Developments
12.9 Nektar Therapeutics
12.9.1 Company Information
12.9.2 Opioid-Induced Constipation Product Offered
12.9.3 Nektar Therapeutics Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2018-2020)
12.9.4 Main Business Overview
12.9.5 Nektar Therapeutics Latest Developments
12.10 Progenics Pharmaceuticals
12.10.1 Company Information
12.10.2 Opioid-Induced Constipation Product Offered
12.10.3 Progenics Pharmaceuticals Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2018-2020)
12.10.4 Main Business Overview
12.10.5 Progenics Pharmaceuticals Latest Developments
12.11 Prestige
12.11.1 Company Information
12.11.2 Opioid-Induced Constipation Product Offered
12.11.3 Prestige Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2018-2020)
12.11.4 Main Business Overview
12.11.5 Prestige Latest Developments
12.12 Shionogi
12.12.1 Company Information
12.12.2 Opioid-Induced Constipation Product Offered
12.12.3 Shionogi Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2018-2020)
12.12.4 Main Business Overview
12.12.5 Shionogi Latest Developments
12.13 GSK
12.13.1 Company Information
12.13.2 Opioid-Induced Constipation Product Offered
12.13.3 GSK Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2018-2020)
12.13.4 Main Business Overview
12.13.5 GSK Latest Developments
13 Research Findings and Conclusion
Tables and Figures
List of Tables
Table 1. Research Methodology
Table 2. Data Source
Table 3. Opioid-Induced Constipation Consumption CAGR by Region 2015-2025 ($ Millions)
Table 4. Major Players of Methylnaltrexone Bromide
Table 5. Major Players of Lubiprostone
Table 6. Major Players of Naloxegol
Table 7. Major Players of Others
Table 8. Global Consumption Sales by Type (2015-2020)
Table 9. Global Opioid-Induced Constipation Consumption Market Share by Type (2015-2020)
Table 10. Global Opioid-Induced Constipation Revenue by Type (2015-2020) ($ million)
Table 11. Global Opioid-Induced Constipation Value Market Share by Type (2015-2020) ($ Millions)
Table 12. Global Opioid-Induced Constipation Sale Price by Type (2015-2020)
Table 13. Global Consumption Sales by Application (2015-2020)
Table 14. Global Opioid-Induced Constipation Consumption Market Share by Application (2015-2020)
Table 15. Global Opioid-Induced Constipation Value by Application (2015-2020)
Table 16. Global Opioid-Induced Constipation Value Market Share by Application (2015-2020)
Table 17. Global Opioid-Induced Constipation Sale Price by Application (2015-2020)
Table 18. Global Opioid-Induced Constipation Sales by Company (2017-2019) (K Units)
Table 19. Global Opioid-Induced Constipation Sales Market Share by Company (2017-2019)
Table 20. Global Opioid-Induced Constipation Revenue by Company (2017-2019) ($ Millions)
Table 21. Global Opioid-Induced Constipation Revenue Market Share by Company (2017-2019)
Table 22. Global Opioid-Induced Constipation Sale Price by Company (2017-2019)
Table 23. Global Opioid-Induced Constipation Manufacturing Base Distribution and Sales Area by Manufacturers
Table 24. Players Opioid-Induced Constipation Products Offered
Table 25. Opioid-Induced Constipation Concentration Ratio (CR3, CR5 and CR10) (2017-2019)
Table 26. Global Opioid-Induced Constipation Consumption by Regions 2015-2020 (K Units)
Table 27. Global Opioid-Induced Constipation Consumption Market Share by Regions 2015-2020
Table 28. Global Opioid-Induced Constipation Value by Regions 2015-2020 ($ Millions)
Table 29. Global Opioid-Induced Constipation Value Market Share by Regions 2015-2020
Table 30. Americas Opioid-Induced Constipation Consumption by Countries (2015-2020) (K Units)
Table 31. Americas Opioid-Induced Constipation Consumption Market Share by Countries (2015-2020)
Table 32. Americas Opioid-Induced Constipation Value by Countries (2015-2020) ($ Millions)
Table 33. Americas Opioid-Induced Constipation Value Market Share by Countries (2015-2020)
Table 34. Americas Opioid-Induced Constipation Consumption by Type (2015-2020) (K Units)
Table 35. Americas Opioid-Induced Constipation Consumption Market Share by Type (2015-2020)
Table 36. Americas Opioid-Induced Constipation Consumption by Application (2015-2020) (K Units)
Table 37. Americas Opioid-Induced Constipation Consumption Market Share by Application (2015-2020)
Table 38. APAC Opioid-Induced Constipation Consumption by Countries (2015-2020) (K Units)
Table 39. APAC Opioid-Induced Constipation Consumption Market Share by Countries (2015-2020)
Table 40. APAC Opioid-Induced Constipation Value by Regions (2015-2020) ($ Millions)
Table 41. APAC Opioid-Induced Constipation Value Market Share by Regions (2015-2020)
Table 42. APAC Opioid-Induced Constipation Consumption by Type (2015-2020) (K Units)
Table 43. APAC Opioid-Induced Constipation Consumption Market Share by Type (2015-2020)
Table 44. APAC Opioid-Induced Constipation Consumption by Application (2015-2020) (K Units)
Table 45. APAC Opioid-Induced Constipation Consumption Market Share by Application (2015-2020)
Table 46. Europe Opioid-Induced Constipation Consumption by Countries (2015-2020) (K Units)
Table 47. Europe Opioid-Induced Constipation Consumption Market Share by Countries (2015-2020)
Table 48. Europe Opioid-Induced Constipation Value by Countries (2015-2020) ($ Millions)
Table 49. Europe Opioid-Induced Constipation Value Market Share by Countries (2015-2020)
Table 50. Europe Opioid-Induced Constipation Consumption by Type (2015-2020) (K Units)
Table 51. Europe Opioid-Induced Constipation Consumption Market Share by Type (2015-2020)
Table 52. Europe Opioid-Induced Constipation Consumption by Application (2015-2020) (K Units)
Table 53. Europe Opioid-Induced Constipation Consumption Market Share by Application (2015-2020)
Table 54. Middle East & Africa Opioid-Induced Constipation Consumption by Countries (2015-2020) (K Units)
Table 55. Middle East & Africa Opioid-Induced Constipation Consumption Market Share by Countries (2015-2020)
Table 56. Middle East & Africa Opioid-Induced Constipation Value by Countries (2015-2020) ($ Millions)
Table 57. Middle East & Africa Opioid-Induced Constipation Value Market Share by Countries (2015-2020)
Table 58. Middle East & Africa Opioid-Induced Constipation Consumption by Type (2015-2020) (K Units)
Table 59. Middle East & Africa Opioid-Induced Constipation Consumption Market Share by Type (2015-2020)
Table 60. Middle East & Africa Opioid-Induced Constipation Consumption by Application (2015-2020) (K Units)
Table 61. Middle East & Africa Opioid-Induced Constipation Consumption Market Share by Application (2015-2020)
Table 62. Opioid-Induced Constipation Distributors List
Table 63. Opioid-Induced Constipation Customer List
Table 64. Global Opioid-Induced Constipation Consumption Forecast by Countries (2021-2025) (K Units)
Table 65. Global Opioid-Induced Constipation Consumption Market Forecast by Regions
Table 66. Global Opioid-Induced Constipation Value Forecast by Countries (2021-2025) ($ Millions)
Table 67. Global Opioid-Induced Constipation Value Market Share Forecast by Regions
Table 68. Global Opioid-Induced Constipation Consumption Forecast by Type (2021-2025) (K Units)
Table 69. Global Opioid-Induced Constipation Consumption Market Share Forecast by Type (2021-2025)
Table 70. Global Opioid-Induced Constipation Value Forecast by Type (2021-2025) ($ Millions)
Table 71. Global Opioid-Induced Constipation Value Market Share Forecast by Type (2021-2025)
Table 72. Global Opioid-Induced Constipation Consumption Forecast by Application (2021-2025) (K Units)
Table 73. Global Opioid-Induced Constipation Consumption Market Share Forecast by Application (2021-2025)
Table 74. Global Opioid-Induced Constipation Value Forecast by Application (2021-2025) ($ Millions)
Table 75. Global Opioid-Induced Constipation Value Market Share Forecast by Application (2021-2025)
Table 76. Takeda Pharmaceuticals Product Offered
Table 77. Takeda Pharmaceuticals Opioid-Induced Constipation Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2020E)
Table 78. Takeda Pharmaceuticals Main Business
Table 79. Takeda Pharmaceuticals Latest Developments
Table 80. Takeda Pharmaceuticals Basic Information, Company Total Revenue (in $ million), Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors
Table 81. Daiichi Sankyo Product Offered
Table 82. Daiichi Sankyo Opioid-Induced Constipation Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2020E)
Table 83. Daiichi Sankyo Main Business
Table 84. Daiichi Sankyo Latest Developments
Table 85. Daiichi Sankyo Basic Information, Company Total Revenue (in $ million), Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors
Table 86. Bayer Product Offered
Table 87. Bayer Opioid-Induced Constipation Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2020E)
Table 88. Bayer Main Business
Table 89. Bayer Latest Developments
Table 90. Bayer Basic Information, Company Total Revenue (in $ million), Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors
Table 91. Mallinckrodt Product Offered
Table 92. Mallinckrodt Opioid-Induced Constipation Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2020E)
Table 93. Mallinckrodt Main Business
Table 94. Mallinckrodt Latest Developments
Table 95. Mallinckrodt Basic Information, Company Total Revenue (in $ million), Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors
Table 96. Salix (Bausch Health) Product Offered
Table 97. Salix (Bausch Health) Opioid-Induced Constipation Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2020E)
Table 98. Salix (Bausch Health) Main Business
Table 99. Salix (Bausch Health) Latest Developments
Table 100. Salix (Bausch Health) Basic Information, Company Total Revenue (in $ million), Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors
Table 101. Sanofi Product Offered
Table 102. Sanofi Opioid-Induced Constipation Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2020E)
Table 103. Sanofi Main Business
Table 104. Sanofi Latest Developments
Table 105. Sanofi Basic Information, Company Total Revenue (in $ million), Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors
Table 106. Purdue Pharm Product Offered
Table 107. Purdue Pharm Basic Information, Company Total Revenue (in $ million), Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors
Table 108. Purdue Pharm Main Business
Table 109. Purdue Pharm Latest Developments
Table 110. Purdue Pharm Opioid-Induced Constipation Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2020E)
Table 111. AstraZeneca Product Offered
Table 112. AstraZeneca Opioid-Induced Constipation Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2020E)
Table 113. AstraZeneca Main Business
Table 114. AstraZeneca Latest Developments
Table 115. AstraZeneca Basic Information, Company Total Revenue (in $ million), Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors
Table 116. Nektar Therapeutics Product Offered
Table 117. Nektar Therapeutics Opioid-Induced Constipation Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2020E)
Table 118. Nektar Therapeutics Main Business
Table 119. Nektar Therapeutics Latest Developments
Table 120. Nektar Therapeutics Basic Information, Company Total Revenue (in $ million), Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors
Table 121. Progenics Pharmaceuticals Product Offered
Table 122. Progenics Pharmaceuticals Opioid-Induced Constipation Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2020E)
Table 123. Progenics Pharmaceuticals Main Business
Table 124. Progenics Pharmaceuticals Latest Developments
Table 125. Progenics Pharmaceuticals Basic Information, Company Total Revenue (in $ million), Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors
Table 126. Prestige Product Offered
Table 127. Prestige Opioid-Induced Constipation Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2020E)
Table 128. Prestige Main Business
Table 129. Prestige Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table 130. Prestige Latest Developments
Table 131. Shionogi Product Offered
Table 132. Shionogi Opioid-Induced Constipation Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2020E)
Table 133. Shionogi Main Business
Table 134. Shionogi Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table 135. Shionogi Latest Developments
Table 136. GSK Product Offered
Table 137. GSK Opioid-Induced Constipation Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2020E)
Table 138. GSK Main Business
Table 139. GSK Latest Developments
Table 140. GSK Basic Information, Manufacturing Base, Sales Area and Its Competitors
List of Figures
Figure 1. Picture of Opioid-Induced Constipation
Figure 2. Opioid-Induced Constipation Report Years Considered
Figure 3. Market Research Methodology
Figure 4. Global Opioid-Induced Constipation Consumption Growth Rate 2015-2025 (K Units)
Figure 5. Global Opioid-Induced Constipation Value Growth Rate 2015-2025 ($ Millions)
Figure 6. Product Picture of Methylnaltrexone Bromide
Figure 7. Product Picture of Lubiprostone
Figure 8. Product Picture of Naloxegol
Figure 9. Product Picture of Others
Figure 10. Global Opioid-Induced Constipation Consumption Market Share by Type (2015-2020)
Figure 11. Global Opioid-Induced Constipation Value Market Share by Type (2015-2020)
Figure 12. Opioid-Induced Constipation Consumed in Hospital
Figure 13. Global Opioid-Induced Constipation Market: Hospital (2015-2020) (K Units)
Figure 14. Global Opioid-Induced Constipation Market: Hospital (2015-2020) ($ Millions)
Figure 15. Opioid-Induced Constipation Consumed in Pharmacy
Figure 16. Global Opioid-Induced Constipation Market: Pharmacy (2015-2020) (K Units)
Figure 17. Global Opioid-Induced Constipation Market: Pharmacy (2015-2020) ($ Millions)
Figure 18. Global Opioid-Induced Constipation Consumption Market Share by Application (2015-2020)
Figure 19. Global Opioid-Induced Constipation Value Market Share by Application (2015-2020)
Figure 20. Global Opioid-Induced Constipation Sales Market Share by Company in 2017
Figure 21. Global Opioid-Induced Constipation Sales Market Share by Company in 2019
Figure 22. Global Opioid-Induced Constipation Revenue Market Share by Company in 2017
Figure 23. Global Opioid-Induced Constipation Revenue Market Share by Company in 2019
Figure 24. Global Opioid-Induced Constipation Sale Price by Company in 2019
Figure 25. Global Opioid-Induced Constipation Consumption Market Share by Regions 2015-2020
Figure 26. Global Opioid-Induced Constipation Value Market Share by Regions 2015-2020
Figure 27. Americas Opioid-Induced Constipation Consumption 2015-2020 (K Units)
Figure 28. Americas Opioid-Induced Constipation Value 2015-2020 ($ Millions)
Figure 29. APAC Opioid-Induced Constipation Consumption 2015-2020 (K Units)
Figure 30. APAC Opioid-Induced Constipation Value 2015-2020 ($ Millions)
Figure 31. Europe Opioid-Induced Constipation Consumption 2015-2020 (K Units)
Figure 32. Europe Opioid-Induced Constipation Value 2015-2020 ($ Millions)
Figure 33. Middle East & Africa Opioid-Induced Constipation Consumption 2015-2020 (K Units)
Figure 34. Middle East & Africa Opioid-Induced Constipation Value 2015-2020 ($ Millions)
Figure 35. Americas Opioid-Induced Constipation Consumption Market Share by Countries in 2019
Figure 36. Americas Opioid-Induced Constipation Value Market Share by Countries in 2019
Figure 37. Americas Opioid-Induced Constipation Consumption Market Share by Type in 2019
Figure 38. Americas Opioid-Induced Constipation Consumption Market Share by Application in 2019
Figure 39. United States Opioid-Induced Constipation Consumption Growth 2015-2020 (K Units)
Figure 40. United States Opioid-Induced Constipation Value Growth 2015-2020 ($ Millions)
Figure 41. Canada Opioid-Induced Constipation Consumption Growth 2015-2020 (K Units)
Figure 42. Canada Opioid-Induced Constipation Value Growth 2015-2020 ($ Millions)
Figure 43. Mexico Opioid-Induced Constipation Consumption Growth 2015-2020 (K Units)
Figure 44. Mexico Opioid-Induced Constipation Value Growth 2015-2020 ($ Millions)
Figure 45. APAC Opioid-Induced Constipation Consumption Market Share by Countries in 2019
Figure 46. APAC Opioid-Induced Constipation Value Market Share by Regions in 2019
Figure 47. APAC Opioid-Induced Constipation Consumption Market Share by Type in 2019
Figure 48. APAC Opioid-Induced Constipation Consumption Market Share by Application in 2019
Figure 49. China Opioid-Induced Constipation Consumption Growth 2015-2020 (K Units)
Figure 50. China Opioid-Induced Constipation Value Growth 2015-2020 ($ Millions)
Figure 51. Japan Opioid-Induced Constipation Consumption Growth 2015-2020 (K Units)
Figure 52. Japan Opioid-Induced Constipation Value Growth 2015-2020 ($ Millions)
Figure 53. Korea Opioid-Induced Constipation Consumption Growth 2015-2020 (K Units)
Figure 54. Korea Opioid-Induced Constipation Value Growth 2015-2020 ($ Millions)
Figure 55. Southeast Asia Opioid-Induced Constipation Consumption Growth 2015-2020 (K Units)
Figure 56. Southeast Asia Opioid-Induced Constipation Value Growth 2015-2020 ($ Millions)
Figure 57. India Opioid-Induced Constipation Consumption Growth 2015-2020 (K Units)
Figure 58. India Opioid-Induced Constipation Value Growth 2015-2020 ($ Millions)
Figure 59. Australia Opioid-Induced Constipation Consumption Growth 2015-2020 (K Units)
Figure 60. Australia Opioid-Induced Constipation Value Growth 2015-2020 ($ Millions)
Figure 61. Europe Opioid-Induced Constipation Consumption Market Share by Countries in 2019
Figure 62. Europe Opioid-Induced Constipation Value Market Share by Countries in 2019
Figure 63. Europe Opioid-Induced Constipation Consumption Market Share by Type in 2019
Figure 64. Europe Opioid-Induced Constipation Consumption Market Share by Application in 2019
Figure 65. Germany Opioid-Induced Constipation Consumption Growth 2015-2020 (K Units)
Figure 66. Germany Opioid-Induced Constipation Value Growth 2015-2020 ($ Millions)
Figure 67. France Opioid-Induced Constipation Consumption Growth 2015-2020 (K Units)
Figure 68. France Opioid-Induced Constipation Value Growth 2015-2020 ($ Millions)
Figure 69. UK Opioid-Induced Constipation Consumption Growth 2015-2020 (K Units)
Figure 70. UK Opioid-Induced Constipation Value Growth 2015-2020 ($ Millions)
Figure 71. Italy Opioid-Induced Constipation Consumption Growth 2015-2020 (K Units)
Figure 72. Italy Opioid-Induced Constipation Value Growth 2015-2020 ($ Millions)
Figure 73. Russia Opioid-Induced Constipation Consumption Growth 2015-2020 (K Units)
Figure 74. Russia Opioid-Induced Constipation Value Growth 2015-2020 ($ Millions)
Figure 75. Middle East & Africa Opioid-Induced Constipation Consumption Market Share by Countries in 2019
Figure 76. Middle East & Africa Opioid-Induced Constipation Value Market Share by Countries in 2019
Figure 77. Middle East & Africa Opioid-Induced Constipation Consumption Market Share by Type in 2019
Figure 78. Middle East & Africa Opioid-Induced Constipation Consumption Market Share by Application in 2019
Figure 79. Egypt Opioid-Induced Constipation Consumption Growth 2015-2020 (K Units)
Figure 80. Egypt Opioid-Induced Constipation Value Growth 2015-2020 ($ Millions)
Figure 81. South Africa Opioid-Induced Constipation Consumption Growth 2015-2020 (K Units)
Figure 82. South Africa Opioid-Induced Constipation Value Growth 2015-2020 ($ Millions)
Figure 83. Israel Opioid-Induced Constipation Consumption Growth 2015-2020 (K Units)
Figure 84. Israel Opioid-Induced Constipation Value Growth 2015-2020 ($ Millions)
Figure 85. Turkey Opioid-Induced Constipation Consumption Growth 2015-2020 (K Units)
Figure 86. Turkey Opioid-Induced Constipation Value Growth 2015-2020 ($ Millions)
Figure 87. GCC Countries Opioid-Induced Constipation Consumption Growth 2015-2020 (K Units)
Figure 88. GCC Countries Opioid-Induced Constipation Value Growth 2015-2020 ($ Millions)
Figure 89. Global Opioid-Induced Constipation Consumption Growth Rate Forecast (2021-2025) (K Units)
Figure 90. Global Opioid-Induced Constipation Value Growth Rate Forecast (2021-2025) ($ Millions)
Figure 91. Americas Opioid-Induced Constipation Consumption 2021-2025 (K Units)
Figure 92. Americas Opioid-Induced Constipation Value 2021-2025 ($ Millions)
Figure 93. APAC Opioid-Induced Constipation Consumption 2021-2025 (K Units)
Figure 94. APAC Opioid-Induced Constipation Value 2021-2025 ($ Millions)
Figure 95. Europe Opioid-Induced Constipation Consumption 2021-2025 (K Units)
Figure 96. Europe Opioid-Induced Constipation Value 2021-2025 ($ Millions)
Figure 97. Middle East & Africa Opioid-Induced Constipation Consumption 2021-2025 (K Units)
Figure 98. Middle East & Africa Opioid-Induced Constipation Value 2021-2025 ($ Millions)
Figure 99. United States Opioid-Induced Constipation Consumption 2021-2025 (K Units)
Figure 100. United States Opioid-Induced Constipation Value 2021-2025 ($ Millions)
Figure 101. Canada Opioid-Induced Constipation Consumption 2021-2025 (K Units)
Figure 102. Canada Opioid-Induced Constipation Value 2021-2025 ($ Millions)
Figure 103. Mexico Opioid-Induced Constipation Consumption 2021-2025 (K Units)
Figure 104. Mexico Opioid-Induced Constipation Value 2021-2025 ($ Millions)
Figure 105. Brazil Opioid-Induced Constipation Consumption 2021-2025 (K Units)
Figure 106. Brazil Opioid-Induced Constipation Value 2021-2025 ($ Millions)
Figure 107. China Opioid-Induced Constipation Consumption 2021-2025 (K Units)
Figure 108. China Opioid-Induced Constipation Value 2021-2025 ($ Millions)
Figure 109. Japan Opioid-Induced Constipation Consumption 2021-2025 (K Units)
Figure 110. Japan Opioid-Induced Constipation Value 2021-2025 ($ Millions)
Figure 111. Korea Opioid-Induced Constipation Consumption 2021-2025 (K Units)
Figure 112. Korea Opioid-Induced Constipation Value 2021-2025 ($ Millions)
Figure 113. Southeast Asia Opioid-Induced Constipation Consumption 2021-2025 (K Units)
Figure 114. Southeast Asia Opioid-Induced Constipation Value 2021-2025 ($ Millions)
Figure 115. India Opioid-Induced Constipation Consumption 2021-2025 (K Units)
Figure 116. India Opioid-Induced Constipation Value 2021-2025 ($ Millions)
Figure 117. Australia Opioid-Induced Constipation Consumption 2021-2025 (K Units)
Figure 118. Australia Opioid-Induced Constipation Value 2021-2025 ($ Millions)
Figure 119. Germany Opioid-Induced Constipation Consumption 2021-2025 (K Units)
Figure 120. Germany Opioid-Induced Constipation Value 2021-2025 ($ Millions)
Figure 121. France Opioid-Induced Constipation Consumption 2021-2025 (K Units)
Figure 122. France Opioid-Induced Constipation Value 2021-2025 ($ Millions)
Figure 123. UK Opioid-Induced Constipation Consumption 2021-2025 (K Units)
Figure 124. UK Opioid-Induced Constipation Value 2021-2025 ($ Millions)
Figure 125. Italy Opioid-Induced Constipation Consumption 2021-2025 (K Units)
Figure 126. Italy Opioid-Induced Constipation Value 2021-2025 ($ Millions)
Figure 127. Russia Opioid-Induced Constipation Consumption 2021-2025 (K Units)
Figure 128. Russia Opioid-Induced Constipation Value 2021-2025 ($ Millions)
Figure 129. Spain Opioid-Induced Constipation Consumption 2021-2025 (K Units)
Figure 130. Spain Opioid-Induced Constipation Value 2021-2025 ($ Millions)
Figure 131. Egypt Opioid-Induced Constipation Consumption 2021-2025 (K Units)
Figure 132. Egypt Opioid-Induced Constipation Value 2021-2025 ($ Millions)
Figure 133. South Africa Opioid-Induced Constipation Consumption 2021-2025 (K Units)
Figure 134. South Africa Opioid-Induced Constipation Value 2021-2025 ($ Millions)
Figure 135. Israel Opioid-Induced Constipation Consumption 2021-2025 (K Units)
Figure 136. Israel Opioid-Induced Constipation Value 2021-2025 ($ Millions)
Figure 137. Turkey Opioid-Induced Constipation Consumption 2021-2025 (K Units)
Figure 138. Turkey Opioid-Induced Constipation Value 2021-2025 ($ Millions)
Figure 139. GCC Countries Opioid-Induced Constipation Consumption 2021-2025 (K Units)
Figure 140. GCC Countries Opioid-Induced Constipation Value 2021-2025 ($ Millions)
Figure 141. Takeda Pharmaceuticals Opioid-Induced Constipation Market Share (2018-2020)
Figure 142. Daiichi Sankyo Opioid-Induced Constipation Market Share (2018-2020)
Figure 143. Bayer Opioid-Induced Constipation Market Share (2018-2020)
Figure 144. Mallinckrodt Opioid-Induced Constipation Market Share (2018-2020)
Figure 145. Salix (Bausch Health) Opioid-Induced Constipation Market Share (2018-2020)
Figure 146. Sanofi Opioid-Induced Constipation Market Share (2018-2020)
Figure 147. Purdue Pharm Opioid-Induced Constipation Market Share (2018-2020)
Figure 148. AstraZeneca Opioid-Induced Constipation Market Share (2018-2020)
Figure 149. Nektar Therapeutics Opioid-Induced Constipation Market Share (2018-2020)
Figure 150. Progenics Pharmaceuticals Opioid-Induced Constipation Market Share (2018-2020)
Figure 151. Prestige Opioid-Induced Constipation Market Share (2018-2020)
Figure 152. Shionogi Opioid-Induced Constipation Market Share (2018-2020)
Figure 153. GSK Opioid-Induced Constipation Market Share (2018-2020)
Reason to Buy
- Current and future of Pharma & Healthcare Market outlook in the developed and emerging markets
- Highlights key business priorities in order to assist companies to realign their business strategies
- The segment that is expected to dominate the Pharma & Healthcare Market
- Regions that are expected to witness the fastest growth during the forecast period
- Identify the latest developments, Pharma & Healthcare Market shares, and strategies employed by the major market players
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the global Pharma & Healthcare Market
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets